Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Shattuck Labs, Inc. (STTK) is a clinical-stage biotechnology company developing innovative dual-function fusion proteins targeting cancer and autoimmune diseases. This page serves as the definitive source for official company announcements, research milestones, and financial updates.
Investors and industry professionals will find timely updates on STTK's clinical trials, regulatory developments, and strategic partnerships. The curated news collection includes press releases on pipeline advancements, collaborations with pharmaceutical leaders, and progress across its proprietary ARC® platform programs.
Key content categories include updates on lead candidates like SL-172154, financial reporting disclosures, and scientific presentations. All materials are sourced directly from company communications to ensure accuracy and compliance.
Bookmark this page for streamlined access to STTK's latest developments in bi-functional therapeutics. Check regularly for critical updates impacting the company's position in immuno-oncology and autoimmune treatment innovation.
Shattuck Labs (NASDAQ: STTK) has appointed Dr. Carrie Brownstein as a new Board member, succeeding Josiah Hornblower, the founder and former Chairman. Dr. Brownstein brings extensive experience from her role as Chief Medical Officer at Cellectis and past positions at major pharmaceutical companies. George Golumbeski, Ph.D., has been appointed as the new Chairman of the Board. This management change is expected to enhance Shattuck's strategic growth as it advances its clinical programs, particularly the SL-172154 candidate.
Shattuck Labs (NASDAQ: STTK) announced it will present four posters at the SITC’s 36th Annual Meeting from November 10-14, 2021. The presentations will cover key studies, including a Phase 1 trial of SL-172154 for platinum-resistant ovarian cancer and SL-279252 for advanced solid tumors. The company's proprietary Agonist Redirected Checkpoint (ARC®) platform aims to enhance cancer treatment by simultaneously blocking immune checkpoints and activating costimulatory pathways. These presentations highlight Shattuck's ongoing commitment to innovative cancer therapies.
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotech firm, announced its participation in three virtual investor conferences in September 2021. CEO Taylor Schreiber will lead discussions at the Citi 16th Annual BioPharma Virtual Conference on September 9, the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, and the Morgan Stanley 19th Annual Global Healthcare Conference on September 15. The company's innovative therapies focus on cancer and autoimmune diseases, including lead programs evaluated in Phase 1 trials.
Shattuck Labs (NASDAQ: STTK) announced the submission of abstracts for Phase 1 dose-escalation data on SL-172154 and SL-279252, to be presented at the SITC Annual Meeting in November 2021. Initial safety data for SL-172154 in ovarian cancer shows an encouraging profile, with plans to expand its study to AML and HR-MDS by Q4 2021. The company reported a net loss of $23.6 million for Q2 2021, an increase from $6.2 million in 2020, while cash reserves of $304.8 million are expected to support operations through 2024.
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology firm, will participate in the BTIG Biotechnology Conference on August 10, 2021. The event will feature a fireside chat with CEO Taylor Schreiber, CMO Lini Pandite, and CFO Andrew Neill at 1:30 p.m. EST. Shattuck focuses on developing bi-functional fusion proteins targeting cancer and autoimmune diseases, with its lead program, SL-172154, currently in a Phase 1 trial. Another compound, SL-279252, is in Phase 1 trials in collaboration with Takeda Pharmaceuticals.
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company, is set to provide a corporate and financial update for Q2 2021 on August 11, 2021, at 4:30 p.m. ET. The earnings call can be accessed via phone and will be available in archived format for up to 90 days afterward. Shattuck focuses on bi-functional fusion proteins to treat cancer and autoimmune diseases, with lead programs SL-172154 and SL-279252 currently in Phase 1 trials. The company leverages its proprietary ARC® platform for innovative therapies.
Shattuck Labs (NASDAQ: STTK) announced the appointment of Abhinav A. Shukla, Ph.D., as Chief Technical Officer. His extensive experience in biologics manufacturing and gene therapy is expected to enhance the company's capabilities in developing its ARC and GADLEN platform compounds. Dr. Shukla previously held senior positions at Redpin Therapeutics and CRISPR Therapeutics, contributing to numerous investigational new drug applications and commercialized therapeutics. Shattuck aims to advance its bi-functional fusion proteins targeting cancer and autoimmune diseases through its innovative platforms.
Shattuck Labs (NASDAQ: STTK) reported Q1 2021 financial results, showing a net loss of $11.8 million, or $0.28 per share, compared to a $6.6 million loss in Q1 2020. Cash and equivalents totaled $321.2 million as of March 31. The company is on track for initial dose-escalation data from its clinical trials of CD47 inhibitor SL-172154 and PD-1 inhibitor SL-279252 in the second half of 2021. R&D expenses rose to $10.3 million, reflecting ongoing clinical developments. Financial guidance indicates sufficient funds to support operations through 2024.
Shattuck Labs (NASDAQ: STTK), a biotechnology firm, announced participation in two upcoming conferences. CEO Taylor Schreiber will discuss multifunctional soluble biologics at the 32nd Annual Cello Health Cancer Progress Conference on May 5, 2021, and ranking product attributes at the 17th Annual PEGS Boston Conference on May 11, 2021. The company focuses on developing bi-functional fusion proteins targeting cancer and autoimmune diseases, led by the SL-172154 program in Phase 1 trials, designed to block immune checkpoints.
Shattuck Labs, Inc. (NASDAQ: STTK) will participate in the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021. CEO Taylor Schreiber and CFO Andrew Neill will engage in a fireside chat at 1:50 p.m. EST. The event will be accessible via a live webcast, with a replay available for 90 days after the presentation. Shattuck specializes in developing bi-functional fusion proteins aimed at treating cancer and autoimmune diseases, leveraging their proprietary ARC® platform.
FAQ
What is the current stock price of Shattuck Labs (STTK)?
What is the market cap of Shattuck Labs (STTK)?
